Related Experiment Video

Updated: Jun 12, 2026

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells
06:29

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells

Published on: July 30, 2020

Aurora A and B kinases--targets of novel anticancer drugs

Silvana Libertini1, Antonella Abagnale, Carmela Passaro

  • 1Dipartiment of Biology and Cellular and Molecular Pathology, School of Medicine, University of Naples Federico II, via s. Pansini 5, 80131 Napoli, Italy.

Recent Patents on Anti-Cancer Drug Discovery
|June 8, 2010
PubMed

Insights

Aurora kinases are crucial for cell division, and their abnormal levels are linked to cancer. Inhibitors targeting Aurora B show therapeutic promise and are under clinical evaluation.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • Aurora kinases are serine-threonine kinases vital for accurate chromosome segregation during mitosis.
  • Aberrant expression of Aurora kinases is frequently observed in various cancers.
  • This has spurred the development of targeted Aurora kinase inhibitors for cancer therapy.

Purpose of the Study:

  • To review the current landscape of Aurora kinase inhibitors.
  • To evaluate their therapeutic potential, particularly focusing on Aurora B as a target.
  • To discuss relevant patents in the field.

Main Methods:

  • Review of preclinical and clinical studies on Aurora kinase inhibitors.
  • Analysis of drug efficacy and specificity for Aurora A and Aurora B.
  • Examination of patent literature related to Aurora kinase inhibitors.

Main Results:

  • Many small molecule inhibitors target both Aurora A and Aurora B with similar efficacy.
  • Observed effects often mimic Aurora B inhibition, suggesting its critical role.
  • Several inhibitors are progressing through preclinical and clinical trials.

Conclusions:

  • Aurora B kinase is a validated and effective therapeutic target for cancer treatment.
  • Aurora kinase inhibitors represent a promising class of anti-cancer drugs.
  • Ongoing research and clinical evaluations are crucial for their successful development.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...